Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 4,606 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (single-dose) Clear all
Completed Phase 2 Interventional Results available

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

NCT02205814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
40 Years to 80 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

NCT01052506
View directory record Official record
Conditions
Healthy
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 9, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

NCT00114699
View directory record Official record
Conditions
HIV Infections
Interventions
CCR5mAb004
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

NCT00404014
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
AL-208, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
50 Years to 79 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Laguna Hills, California • Sacramento, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

NCT03378635
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, GlucaGen, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

NCT04742517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety

NCT02021214
View directory record Official record
Conditions
PTSD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00859755
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ARRY-403, glucokinase activator; oral, Placebo; oral
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

NCT04364789
View directory record Official record
Conditions
Healthy
Interventions
TT-00920, Placebos
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Vitamin B12 in Septic Shock

NCT03783091
View directory record Official record
Conditions
Septic Shock
Interventions
Hydroxocobalamin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

NCT06485258
View directory record Official record
Conditions
Rotavirus Infections
Interventions
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo
Biological · Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808
View directory record Official record
Conditions
Perianal Fistula Due to Crohn's Disease
Interventions
DB-3Q, Placebo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 9, 2026, 10:28 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 9, 2026, 10:28 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

NCT07749768
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
ONO-6414, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT05456490
View directory record Official record
Conditions
Healthy
Interventions
Liposomal Bupivacaine 13.3, Bupivacaine, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Results available

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390
View directory record Official record
Conditions
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions
ANK-700, Placebo
Drug
Lead sponsor
Anokion SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 9, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

NCT02046148
View directory record Official record
Conditions
GBS Disease, Streptococcus Agalactiae
Interventions
GBS trivalent vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 9, 2026, 10:28 AM EDT
Terminated Phase 3 Interventional

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

NCT05111626
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Bemarituzumab, Nivolumab, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Cerritos, California • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 9, 2026, 10:28 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 9, 2026, 10:28 AM EDT